For mild-to-moderate travelers' diarrhea, nifuroxazide is not prescribed. The drug is absent from international recommendations ( 2017, ISTM 2017, 2023) for this indication. First-line options for moderate disease are azithromycin 1000 mg as a single dose or rifaximin 200 mg three times daily for 3 days in the absence of fever and bloody stools. There is no evidence base for prescribing nifuroxazide to travelers.

Sources

IDSA: Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea (2017)
UpToDate: Approach to the adult with acute diarrhea in resource-rich settings (2024)
NICE: Gastroenteritis: management (CKS) (2023)

Notas prácticas

Cuándo y cómo tomar

Where the indication is justified per Russian labeling, tablets 200 mg are taken 4 times daily or suspension 200 mg 4 times daily. The course does not exceed 7 days. The drug is not absorbed systemically and acts locally in the intestinal lumen. Intake is independent of meals. Mandatory parallel rehydration (oral or intravenous in severe cases) is given.

Titulación de dosis

The dose is set per Russian labeling. There is no evidence base for escalation, course extension, or use in additional indications. Persistent symptoms beyond 3 days require diagnostic reassessment and transition to evidence-based regimens per 2017 (azithromycin, ciprofloxacin in severe bacterial diarrhea) or an infectious disease consultation.

Monitorización

No specific laboratory monitoring is required. Key follow-up points are stool dynamics, hydration status, body temperature, and appearance of blood or pus in stools. With deterioration or persistence beyond 3 days, tactics are changed: stool culture, C. difficile testing, and an evidence-based antibiotic in confirmed bacterial infection.

Situaciones especiales

In children under 2 years, the drug is not used per 2019. The decision is based on lack of proven efficacy and reported allergic reactions. In children over 2 years, prescribing is at the physician's discretion in countries where the drug is registered, first and foremost with mandatory rehydration. Fever, blood in stools, or signs of dehydration require hospitalization and revision of therapy.

Mitos frecuentes

Myth: "nifuroxazide is a safe intestinal antiseptic, fits any diarrhea". Fact: international guidelines (, , ) do not list the drug; the evidence base is limited. In 2019 withdrew pediatric forms in some EU countries due to an unfavorable benefit-risk balance.

Myth: "works faster than rehydration". Fact: the foundation of acute diarrhea management is rehydration. Antimicrobials, including nifuroxazide, do not shorten diarrhea in immunocompetent adults with viral etiology.

Myth: "can be used prophylactically while traveling". Fact: nifuroxazide is not recommended for travelers' diarrhea prophylaxis. Prophylactic antibiotics for travelers are not indicated in most cases.

Preguntas frecuentes

What is nifuroxazide used for?

nifuroxazide is evaluated for the following indications with varying evidence strength: Acute infectious diarrhea (evidence tier F), Mild-to-moderate travelers' diarrhea (evidence tier F), Functional non-infectious diarrhea (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of nifuroxazide?

Common side effects of nifuroxazide (≥ 1 in 100): Gastrointestinal discomfort: nausea, bloating, Rash. See the Safety section for uncommon and serious reactions.

Is nifuroxazide safe during pregnancy?

No FDA category assigned: the drug is not registered in the United States. Human safety data in pregnancy are limited. EMA in 2019 emphasized the limited data and unfavorable benefit-risk balance even in children. In pregnancy the drug is not used, because rehydration and supportive therapy on the obstetrician's recommendation are preferred for infectious diarrhea.

Is nifuroxazide compatible with breastfeeding?

Data on passage into breast milk are absent. The drug is not used during lactation. Alternatives are rehydration and symptomatic therapy compatible with breastfeeding.

Who should not take nifuroxazide?

nifuroxazide is contraindicated in: Hypersensitivity to nitrofurans in history; Age under 2 months; Age under 6 years for tablet formulations; Sucrase-isomaltase deficiency, fructose intolerance (for sucrose-containing suspension). Full list in the Safety section.

nifuroxazide is a safe intestinal antiseptic, fits any diarrhea

international guidelines (IDSA, WHO, NICE) do not list the drug; the evidence base is limited. In 2019 EMA withdrew pediatric forms in some EU countries due to an unfavorable benefit-risk balance.

works faster than rehydration

the foundation of acute diarrhea management is rehydration. Antimicrobials, including nifuroxazide, do not shorten diarrhea in immunocompetent adults with viral etiology.

can be used prophylactically while traveling

nifuroxazide is not recommended for travelers' diarrhea prophylaxis. Prophylactic antibiotics for travelers are not indicated in most cases.

nifuroxazide

Mecanismo de acción

Indicaciones

Acute infectious diarrhea

Functional non-infectious diarrhea

Mild-to-moderate travelers' diarrhea

Notas prácticas

Cuándo y cómo tomar

Titulación de dosis

Monitorización

Situaciones especiales

Mitos frecuentes

Seguridad

Contraindicaciones

Reacciones adversas graves

Reacciones adversas frecuentes

Reacciones adversas poco frecuentes

Embarazo

Lactancia

Preguntas frecuentes